None listed
Conditions
Brief summary
Prophylactic antiemetic and analgesic oral premedications are frequently prescribed preoperatively to enhance recovery after laparoscopic gastric sleeve resection. However, it is unknown whether these medications transit beyond the stomach or if they remain in the stomach or sleeve resection specimen, thereby negating their pharmacological effects. The purpose of this study is to identify whether age, sex, body mass index, and diabetes mellitus are associated with the presence or absence of oral premedication in the stomach or resected gastric specimen. Who is it for? The study will include adult patients undergoing bariatric surgery. This is a retrospective analysis of patients who underwent laparoscopic gastric sleeve resection who received premedications as part of usual anaesthesia and surgical care. Study details This study will evaluate the presence or absence of oral premedication in the stomach or sleeve resection specimens. The secondary aims will be to to evaluate whether age, sex, body mass index, or diabetes mellitus are associated with the presence or absence of oral premedication in the stomach or resected gastric specimen. Finally, the study will evaluated the association between premedication lead time and the presence or absence of premedication in the specimen. Premedication lead time is defined as the time in minutes from when the premedication tablets were administered orally to when the gastric sleeve was resected. It is hoped that this study will be hypothesis generating and provide valuable data for power calculations for future studies on evaluating the timing of premedication before bariatric surgery.
Interventions
This is a retrospective analysis of patients who underwent laparoscopic gastric sleeve resection between July 2020 and May 2022 and received oral premedication (tapentadol - slow release and netupitant/palonosetron) as part of their bariatric surgery program. All data were collected during review of the patients' medical records.
The presence and physical state of medications at the time of gastric sleeve resection were recorded.
Patients were then stratified into two groups:
1. Transit grou
This is a retrospective analysis of patients who underwent laparoscopic gastric sleeve resection between July 2020 and May 2022 and received oral premedication (tapentadol - slow release and netupitant/palonosetron) as part of their bariatric surgery program. All data were collected during review of the patients' medical records. The presence and physical state of medications at the time of gastric sleeve resection were recorded. Patients were then stratified into two groups: 1. Transit group (premedication not seen in the stomach or resection specimen) 2. Failure-to-Transit group (premedication present in the resection specimen). We evaluated whether age, sex, body mass index, and diabetes mellitus were associated with the presence or absence of oral premedication in the stomach or resected gastric specimen. The association between the time that the premedications were administered orally and the time that the gastric specimen was resected i.e., the premedication lead time, and the presence or absence of premedication in the specimen was evaluated.
Sponsors
Austin Health - Austin Hospital - Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
We will include the following patients: 1. Aged 18 years or older 2. Undergoing bariatric sleeve gastrectomy between July 2020 and May 2022 for weight loss 3. Received oral premedication as part of their anaesthesia protocol.
Exclusion criteria
We will exclude the following patients 1. Patients undergoing non-resectional procedures including Roux-en-Y gastric bypass, single anastomosis gastric bypass, laparoscopic gastric banding, revisional bariatric surgery 2. Patients on any prokinetic medications 3. Patients those who did not receive premedications.
Outcome results
None listed